IP Verse

Stada Arzneimittel vs. Sanofi - UPC_CFI_496/2024

The UPC Case UPC_CFI_496/2024 was filed on 02 Sep, 2024 by the plaintiff Stada Arzneimittel, Stada Nordic, Stadapharm against the defendant Sanofi, Sanofi AB, Sanofi Aventis, and others.

Case Details

    Case Number:

    UPC_CFI_496/2024

    Patent Number:

    EP2493466

    Filing Date:

    02 Sep, 2024

    Proceeding Type:

    Counter Claim For Revocation

    Case Phase:

    Interim Phase

    Plaintiffs:

    • Stada Arzneimittel
    • Stada Nordic
    • Stadapharm

    Plaintiff Representatives:

    • Konstantin Schallmoser

    Defendants:

    • Sanofi
    • Sanofi AB
    • Sanofi Aventis
    • Sanofi Aventis Deutschland
    • Sanofi Aventis France
    • Sanofi Belgium
    • Sanofi Mature
    • Sanofi Produtos Farmaceuticos LDA
    • Sanofi Winthrop Industrie

    Defendant Representatives:

    • Frédéric CHEVALLIER

    Judges:

    • Alima Zana
    • Matthias Zigann
    • Tobias Pichlmaier

Case Decision

Decision pending - set alert to receive updates

Docket Entries

The docket entries provide a comprehensive overview of all filings, motions, orders, and other significant actions taken in the case.

DateTitleLink
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 9, 2025Rejoinder-
Aug 9, 2025Acknowledgement Of Lodging-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 11, 2025Formal Checks Notification Of Positive Outcome-
Jul 11, 2025Application Rop293 Receipt-
Jul 11, 2025Acknowledgement Of Change Of A Representative-
Jul 10, 2025Application Rop293-
Jul 10, 2025Application-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Rejoinder And Reply Signiert-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Dec 19, 2024Outcome Of The Order-
Dec 19, 2024Extension Request
Dec 13, 2024Receipt-
Dec 12, 2024Extension Request-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Zustellbestatigung E Mail-
Sep 16, 2024Notification Of Service-
Sep 16, 2024Letter For Service-
Sep 16, 2024Document From Epo-
Sep 13, 2024Letter For Service-
Sep 13, 2024Acknowledgement Of Access To Case-
Sep 11, 2024Panel Appointment-
Sep 11, 2024Formal Checks Notification Of Positive Outcome-
Sep 11, 2024Epo Request For Case Pending-
Sep 11, 2024Acknowledgement Of Lodging-
Sep 2, 2024WO96/30355 A1 Published 3 October 1996-
Sep 2, 2024Wo /051894, Original Application-
Sep 2, 2024Wo /028462, Published 31 March-
Sep 2, 2024Winquist Et Al., The Canadian Journal Of Urology, 15(1), February-
Sep 2, 2024Uspto Decision DATED 21 September , Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024US61/256160, First Priority Document-
Sep 2, 2024Us /0065138 A1, Published 24 March-
Sep 2, 2024Un Projet De Medicament Stoppe In Extremis , Les Echos, 22 Dec-
Sep 2, 2024Tribunal Judiciaire De Paris, Ordonnance De Refere, 17 June , Ndeg Rg 21/53849 Ndeg Portalis 352J W B7F Cujg2-
Sep 2, 2024Tannock Et Al., N Engl J Med , 351(15),-
Sep 2, 2024Tannock, Et Al., J. Clin. Oncol. 1996, 14(6), 1756 64.-
Sep 2, 2024Tannock Et Al., J. Clin. Oncol. 1989, 7(5), 590 7.-
Sep 2, 2024T 3165/19 Of The Epo Boards Of Appeal DATED 9 January-
Sep 2, 2024T 2963/19 Of The Epo Boards Of Appeal DATED 18 March-
Sep 2, 2024Summary Of Product Characteristics Of Taxotere; Revision Of November-
Sep 2, 2024Summary Of Product Characteristics Of Jevtana(R), Sanofi Genzyme, April-
Sep 2, 2024Sternberg Et Al. Oncology ;85: 208 215-
Sep 2, 2024Shigeta Et Al., Correspondence, The Lancet, 377, , 121 122-
Sep 2, 2024Sava, Et Al., Expert Rev. Anticancer Ther. , 5(1), 53 62.-
Sep 2, 2024Sartor Et Al., Urology 52 (2), 1998, 252 256-
Sep 2, 2024Sartor, Endpoints In Prostate Cancer Clinical Trials. Urology , 60, 101 108-
Sep 2, 2024Sanofi Press Release, A Promising R&D Portfolio, Well Positioned To Deliver Future Growth , September 17, .-
Sep 2, 2024Sanofi Aventis Press Release, 21 December-
Sep 2, 2024Sanofi Aventis Annual Review, 17 April-
Sep 2, 2024Sanchez Et Al. Prostate (15 September) 69: 1448 1459-
Sep 2, 2024Rosenberg Et Al., Cancer , 110(3), 556 563-
Sep 2, 2024Reuters Newsclip Confirming The Date Of D23 (Ae14)-
Sep 2, 2024Protocol Of Clinical Trial Nct00417079 (Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone In Hormone Ref-
Sep 2, 2024Pivot Et Al., Annals Of Oncology, 19, ,-
Sep 2, 2024Patentee S Response DATED 4 January To The Summons To Oral Proceedings In Examination Proc.-
Sep 2, 2024Pal Et Al., Clinical Interventions In Aging, 5, , 395 402-
Sep 2, 2024Oh Et Al., Urology, , 67:.-
Sep 2, 2024October Version Of The Helsinki Declaration-
Sep 2, 2024Mpep Section 601-
Sep 2, 2024Mita Et Al., Clin Cancer Res ; 15(2) Published 15 January-
Sep 2, 2024List Of Documents From The Epo Opposition Proceedings (Includes Further Documents On Which This Statement Of Defence And-
Sep 2, 2024Leaflet Xrp6258 And Xrp9881 Novel Taxoids By Aventis Pharmaceuticals Inc.,-
Sep 2, 2024Jaehde, Lehrbuch Der Klinischen Pharmazie, Stuttgart Wissenschaftliche Verlagsgesellschaft, 1998, Kapitel 8, Seiten 103-
Sep 2, 2024Ich Harmonised Tripartite Guideline General Considerations For Clinical Trials E8 DATED 17 July 1997-
Sep 2, 2024Guidance Document Entitled Cabazitaxel (Xrp 6258) For Hormone Refractory, Metastatic Prostate Cancer Second Line Afte-
Sep 2, 2024Goetz Et Al., Clinical Pharmacology, Proceedings Of Asco Volume 20-
Sep 2, 2024Galletti Et Al., Chemmedchem , 2, 920 942-
Sep 2, 2024Gaisky Et Al., Nature Reviews, Drug Discovery, 9, , 677-
Sep 2, 2024Fundamental Statistics Educational Slide Module, Date Of Preparation: February , Across T2D Academy For Cardiova-
Sep 2, 2024Fossa, Et Al., J. Clin. Oncol. , 19(1), 62 71.-
Sep 2, 2024Figg Et Al., Cancer Biology & Therapy, 10, ,-
Sep 2, 2024Fda Prescribing Information Of Jevtana (Cabazitaxel); Revised In June-
Sep 2, 2024Fda Label For Taxotere ()-
Sep 2, 2024Extract Relating To Trial No. Nct00417079 DATED 11 September-
Sep 2, 2024Expert Opinion Dr. Kai Gevers DATED 26 March-
Sep 2, 2024Expert Declaration By Prof. Muller Including Annexes 1 To 5 Cited Therein-
Sep 2, 2024Ema Ich Topic E 8 General Considerations For Clinical Trials , Published March 1998.-
Sep 2, 2024Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man,-
Sep 2, 2024Ema Assessment Report For Jevtana (Cabazitaxel), 20 January-
Sep 2, 2024Document Zeltia Junta General De Accionistas , Cited As Document D2 In Epo Boards Of Appeal Decision T 2506/12-
Sep 2, 2024Document Information For The Patient Concerning The Clinical Study 42446 02041 , Cited As Document 55 In Epo Boards O-
Sep 2, 2024Declaration By Prof. Dr Kurt Miller DATED 12 May-
Sep 2, 2024Declaration By Dr Samuel Denmeade DATED 30 April-
Sep 2, 2024Declaration By Dr Oliver Sartor DATED 23 June Filed In Case Ipr2016 00712, Patent Us 8,927,592-
Sep 2, 2024Declaration By Dr. Alton Oliver Sartor, M.D., December 23,-
Sep 2, 2024Decision T 2506/12 Of The Epo Boards Of Appeal DATED 4 October-
Sep 2, 2024Decision T 0239/16, DATED 13 September-
Sep 2, 2024Decision T 0096/20 Of The Epo Boards Of Appeal DATED 22 April-
Sep 2, 2024Decision Of The Epo Boards Of Appeal T1806/18 DATED 21 October-
Sep 2, 2024De Bono Et Al., Lancet, 376, ,-
Sep 2, 2024De Bono Et Al. Article (Cf. D15) As Published On October 2,-
Sep 2, 2024Curriculum VITAE Of Prof. Dr. Kurt Miller-
Sep 2, 2024Counterclaim For Revocation-
Sep 2, 2024Blog Posts By Dr Barry Mirtsching On The Center For Oncology Research & Treatment Dallas, Tx Innovative Cancer Treatmen-
Sep 2, 2024Blog Post By Dr Barry Mirtsching On The Prostate Cancer Blog , DATED 12 October-
Sep 2, 2024Bissery Et Al., Pharmacology And Experimental Therapeutics, Proceedings Of The American Association For Cancer Research-
Sep 2, 2024Berthold Et Al., Ann. Oncol., 19, ,-
Sep 2, 2024Beardsley Et Al., Curr. Op. Support. Palliat. Care , 2(3), 161 166-
Sep 2, 2024Attard Et Al, Pathologie Biologie 54 () 72 84-
Sep 2, 2024Assignment Before The Uspto-
Sep 2, 2024Aller Et Al. Proceedings Of The American Association For Cancer Research , 41: 302, Abstract #1923-
Sep 2, 2024Albarqouni, Tutorial About Hazard Ratios Students 4 Best Evidence , Https://S4Be.Cochrane.Org/Blog//Tutoria-

More cases involving EP2493466B1

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
CC_48036/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie
CC_49716/2024Sep 2, 2024Zentiva, Zentiva France, Zentiva PharmaSanofi Mature
UPC_CFI_503/2024Sep 2, 2024Zentiva, Zentiva France, Zentiva PharmaSanofi Mature

More cases involving Stada Arzneimittel

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
CC_48036/2024Sep 2, 2024Stada ArzneimittelSanofi, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie

More cases involving Sanofi

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
App_34318/2025Aug 5, 2025Sanofi Biotechnology -
ORD_34328/2025Aug 5, 2025AmgenSanofi Aventis Deutschland, Sanofi Aventis Groupe, Sanofi Winthrop Industrie
App_33251/2025Jul 21, 2025Sanofi Biotechnology -